What it is
A community blend combining the pentadecapeptide BPC-157 with the thymosin beta-4 fragment TB-500, supplied as a co-lyophilized powder.
How it works
BPC-157 is studied for nitric-oxide-pathway and angiogenic effects; TB-500 (thymosin beta-4) binds G-actin and may influence cell migration. Human pharmacokinetics of both are poorly characterized.
Where it's used
Used in research/community settings, often combined for soft-tissue recovery contexts based on the preclinical literature on each component.
Regulatory status
Not FDA-approved; research compounds.
Reconstitution
Supplied as a co-lyophilized powder requiring reconstitution with bacteriostatic water prior to use.
Tracking it
BPC-157 / TB-500 is injectable, so two things matter in a log: when you dosed and where. Rotating sites and writing both down prevents the classic “did I already pin the left side?” problem.
Source
Public reference
Last reviewed 2026-06-11